Sebastiaan J W van Kraaij (Sebastiaan van Kraaij)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 9

Top Topics

Cerebrospinal Fluid

Top Venues

Clinical and translational science

British journal of clinical pharmacology

Immunologic research

Clinical physiology and functional imaging

This page only lists publications with an associated author ORCID identifier.

Publications

Sebastiaan J W van Kraaij, Boukje C Eveleens Maarse, Femke P M Hoevenaars, Ines Warnke, Marieke L de Kam, Matthijs Moerland, Pim Gal
Microvascular effects of a mixed meal tolerance test: a model validation study. Clinical physiology and functional imaging (2024)
Marella C E van Ruissen, Sebastiaan J W van Kraaij, Pim Gal, Wouter A Bakker, Hemme J Hijma, Geert Jan Groeneveld, Marieke L de Kam, Jacobus Burggraaf, Matthijs Moerland
Open-Label Interventional Study in Healthy Volunteers to Evaluate NO-Mediated Vasodilation by Dermal Allyl Isothiocyanate Challenge and Whole-Body Heat Stress. Journal of experimental pharmacology 16 (2024)
Sebastiaan J W van Kraaij, Rainer-Georg Goeldner, Holger Rosenbrock, Geert Jan Groeneveld, Philip Kremer, Jennifer Schaible, Janos Zambori, Christian Schultheis
Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies. British journal of clinical pharmacology (2024)
Sebastiaan J W van Kraaij, Diana R Pereira, Bastiaan Smal, Luciana Summo, Anne Konkel, Janine Lossie, Andreas Busjahn, Tom N Grammatopoulos, Erica Surya Klaassen, Robert Fischer, Wolf-Hagen Schunck, Pim Gal, Matthijs Moerland
Identification of peripheral vascular function measures and circulating biomarkers of mitochondrial function in patients with mitochondrial disease. Clinical and translational science (2023)
Sebastiaan J W van Kraaij, Pim Gal, Laura G J M Borghans, Erica Surya Klaassen, Francis Dijkstra, Christopher Winrow, Chad Glasser, Geert Jan Groeneveld
First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator. Clinical and translational science (2023)
Aliede E In 't Veld, Hendrika W Grievink, Johan L van der Plas, Boukje C Eveleens Maarse, Sebastiaan J W van Kraaij, Tess D Woutman, Mascha Schoonakker, Naomi B Klarenbeek, Marieke L de Kam, Ingrid M C Kamerling, Manon A A Jansen, Matthijs Moerland
Immunosuppression by hydroxychloroquine: mechanistic proof in in vitro experiments but limited systemic activity in a randomized placebo-controlled clinical pharmacology study. Immunologic research (2023)
Sebastiaan J W van Kraaij, Pim Gal, Laura G J M Borghans, Erica Surya Klaassen, Francis Dijkstra, Christopher Winrow, Chad Glasser, Geert Jan Groeneveld
First-in-human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator. Clinical and translational science (2023)
Aliede E In 't Veld, Hendrika W Grievink, Johan L van der Plas, Boukje C Eveleens Maarse, Sebastiaan J W van Kraaij, Tess D Woutman, Mascha Schoonakker, Naomi B Klarenbeek, Marieke L de Kam, Ingrid M C Kamerling, Manon A A Jansen, Matthijs Moerland
Immunosuppression by hydroxychloroquine: mechanistic proof in in vitro experiments but limited systemic activity in a randomized placebo-controlled clinical pharmacology study. Immunologic research (2023)
Sebastiaan J W van Kraaij, Laura G J M Borghans, Erica S Klaassen, Pim Gal, Jeroen van der Grond, Ken Tripp, Christopher Winrow, Chad Glasser, Geert Jan Groeneveld
Randomized placebo-controlled crossover study to assess tolerability and pharmacodynamics of zagociguat, a soluble guanylyl cyclase stimulator, in healthy elderly. British journal of clinical pharmacology (2023)